These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29921210)

  • 41. A Complex Intervention to Prevent Medication-Related Hospital Admissions.
    Neubert A; Toni I; König J; Malonga Makosi D; Mildenberger P; Romanos M; Bertsche A; Bertsche T; Dahlem P; Egberts K; Erdlenbruch B; Fekete S; Haug U; Horneff G; Hübler A; Kiess W; Neininger MP; Niehues T; Sachs B; Schettler KF; Schreeck F; Steimle T; Wenzl T; Wirth S; Zepp F; Schwab M; Urschitz MS; Rascher W;
    Dtsch Arztebl Int; 2023 Jun; 120(25):425-431. PubMed ID: 37278031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.
    Borysowski J; Ehni HJ; Górski A
    Br J Clin Pharmacol; 2019 Oct; 85(10):2448-2449. PubMed ID: 31410871
    [No Abstract]   [Full Text] [Related]  

  • 43. Off-label use of cardiovascular drugs as an indicator of therapeutic need in paediatrics.
    Cammarata SM; Capone G
    Eur J Hosp Pharm; 2024 Feb; 31(2):179. PubMed ID: 36737229
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug related adverse event assessment in neonates in clinical trials and clinical care.
    Yalcin N; van den Anker J; Samiee-Zafarghandy S; Allegaert K
    Expert Rev Clin Pharmacol; 2024 Sep; 17(9):803-816. PubMed ID: 39129478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crucial need for improved pharmacovigilance in pregnancy.
    Mofenson LM; Abrams EJ
    Lancet HIV; 2023 Sep; 10(9):e560-e562. PubMed ID: 37506722
    [No Abstract]   [Full Text] [Related]  

  • 46. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients.
    Liu R; Wang L; Rizzo S; Garmhausen MR; Pal N; Waliany S; McGough S; Lin YG; Huang Z; Neal J; Copping R; Zou J
    Cell Rep Med; 2024 Mar; 5(3):101444. PubMed ID: 38428426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Knowledge discovery of drug data on the example of adverse reaction prediction.
    Yildirim P; Majnarić L; Ekmekci O; Holzinger A
    BMC Bioinformatics; 2014; 15 Suppl 6(Suppl 6):S7. PubMed ID: 25079450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse Drug Events Presented in Health Institutions in Monteria, Colombia, 2018-2021.
    Martínez M; Villa-Dangond HS; López EM; Guzmán C
    J Multidiscip Healthc; 2023; 16():3887-3895. PubMed ID: 38084121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dermatologists and pharmacovigilance practitioners: A winning partnership for the management of cutaneous adverse drug reactions.
    Lebrun-Vignes B
    Ann Dermatol Venereol; 2023 Sep; 150(3):169-170. PubMed ID: 37640574
    [No Abstract]   [Full Text] [Related]  

  • 50. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.
    Zito JM; Derivan AT; Kratochvil CJ; Safer DJ; Fegert JM; Greenhill LL
    Child Adolesc Psychiatry Ment Health; 2008 Sep; 2(1):24. PubMed ID: 18793403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comment: Is off-label medication use in the ICU a problem?
    Cotta MO; Roberts JA; Reade MC
    Crit Care; 2023 Jul; 27(1):288. PubMed ID: 37454194
    [No Abstract]   [Full Text] [Related]  

  • 52. Letter: Getting patients to take medication.
    N Engl J Med; 1973 Nov; 289(18):983-4. PubMed ID: 4743631
    [No Abstract]   [Full Text] [Related]  

  • 53. The value of registries for rare and severe adverse events in paediatrics.
    Prescott RJ
    Lancet Child Adolesc Health; 2024 Jun; 8(6):389-390. PubMed ID: 38697176
    [No Abstract]   [Full Text] [Related]  

  • 54. Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies.
    Lapeyre-Mestre M
    EClinicalMedicine; 2019 Dec; 17():100216. PubMed ID: 31891147
    [No Abstract]   [Full Text] [Related]  

  • 55. Anticipating, investigating and managing the adverse effects of drugs.
    Pirmohamed M
    Clin Med (Lond); 2005; 5(1):23-6. PubMed ID: 15745193
    [No Abstract]   [Full Text] [Related]  

  • 56. Diclofenac in adolescents: diagnosing and treating gastrointestinal adverse drug reactions can prevent future deaths.
    Thomas ET; Richards GC
    BMJ Evid Based Med; 2021 Feb; ():. PubMed ID: 33568352
    [No Abstract]   [Full Text] [Related]  

  • 57. Two decades of off-label prescribing in children: a literature review.
    Balan S; Hassali MAA; Mak VSL
    World J Pediatr; 2018 Dec; 14(6):528-540. PubMed ID: 30218415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations.
    Jiang K; Poppenberg KE; Wong L; Chen Y; Borowitz D; Goetz D; Sheehan D; Frederick C; Tutino VM; Meng H; Jarvis JN
    J Cyst Fibros; 2019 Mar; 18(2):194-202. PubMed ID: 29941318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Off-label Medication Prescribing Patterns in Pediatrics: An Update.
    Yackey K; Stukus K; Cohen D; Kline D; Zhao S; Stanley R
    Hosp Pediatr; 2019 Mar; 9(3):186-193. PubMed ID: 30745323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy of Off-label and Unlicensed Medicines in Children.
    Lee JH; Byon HJ; Choi S; Jang YE; Kim EH; Kim JT; Kim HS
    J Korean Med Sci; 2018 Sep; 33(37):e227. PubMed ID: 30190655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.